Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intellectual Property Protection: Foreign Governments Get To Argue Their Case To USTR Before Publication Of "Watch Lists"

This article was originally published in PharmAsia News

Executive Summary

For the first time, the U.S. Trade Representative is giving foreign governments and others a chance to publicly testify before issuing its 2010 Special 301 report on countries it deems do not provide adequate protection of intellectual property rights

You may also be interested in...



Forced Technology Transfer Hinders Innovation In China – USTR

China still has major intellectual property enforcement problems that unfairly disadvantage U.S. IP rights holders in the country.

President Obama May Take Up IP Protection Issue During India Visit

MUMBAI - One of the top priorities for U.S. President Barack Obama during his four day visit to India may be to seek strengthened IP rights protection from the Indian government - a thorny issue that has kept some multinational companies away from committing R&D investments in the country despite availability of a large pool of scientists and significant cost advantages

President Obama May Take Up IP Protection Issue During India Visit

MUMBAI - One of the top priorities for U.S. President Barack Obama during his four day visit to India may be to seek strengthened IP rights protection from the Indian government - a thorny issue that has kept some multinational companies away from committing R&D investments in the country despite availability of a large pool of scientists and significant cost advantages

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel